Midostaurin a cost effective option for AML in Canada
Midostaurin "represents a new cost effective option" when combined with standard of care in patients with newly diagnosed FLT3 mutation positive acute myeloid leukaemia (AML) in Canada, according to the results of a study* presented at the 23rd Annual Meeting of ISPOR. The researchers developed a partition survival model to compare the costs and outcomes of midostaurin standard of care, followed by midostaurin maintenance, versus standard of care alone over a 15 year time horizon. Input data were obtained from the phase III, RATIFY trial and other published data sources. Direct medical costs were included, and costs and benefits were discounted at a rate of 1.5% per annum. Overall, midostaurin was associated with incremental life year (LY) and QALY gains, compared with standard of care alone (0.72 and 0.85, respectively) Over the 15 year time horizon, midostaurin resulted in incremental costs of $Can79 147 per LY and $66 937 per QALY versus standard of care alone.
PharmacoEconomics Outcomes News